Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Northwest Biotherapeutics has again started patient recruitment in an ongoing double blind, randomized, placebo controlled Phase II clinical trial evaluating DCVax for Glioblastoma multiforme (GBM) brain cancer.
Subscribe to our email newsletter
The trial has already recruited 240-patients.
The only aspect of the trial that stopped for a period of time was the enrollment of additional new patients beyond the 33 patients who were already enrolled and receiving ongoing treatment.
Northwest said that in Phase I studies, DCVax have showed positive results with a number of patients living more than 3 years.
Principal investigator of the study Linda Liau said after more than 10 years of development, DCVax is poised to make a real difference in the future treatment of brain cancer.
"DCVax is at the forefront of personalized therapy, which offers great potential for improving patients’ outcomes," Liau said.